Peptide Therapeutics Market

Peptide Therapeutics Market (Application: Cancer, Metabolic, CVD, Respiratory, GIT, Anti-infective, Dermatology, CNS, and Renal) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Peptide Therapeutics Market Outlook 2031

  • The global market was valued at US$ 39.34 Bn in 2021
  • The global market is projected to grow at a CAGR of 8.8% from 2022 to 2031
  • The global peptide therapeutics market is anticipated to reach more than US$ 91.25 Bn by 2031

Analysts’ Viewpoint on Global Market Scenario

Sedentary lifestyle and unhealthy diet are leading to a surge in prevalence and incidence of chronic diseases. High incidence and prevalence of metabolic disorders is expected to drive the global market in the next few years. Growth in geriatric population across the globe is also expected to boost the global market for peptide therapeutics. Peptides are now being widely used in therapeutic applications of cancer and chronic metabolic diseases due to advancements in technology. Rise in prevalence of cancer among the geriatric population is anticipated to increase the demand for new peptide therapeutics. Industry players are investing in research and development activities to introduce new peptide therapeutics in order to address this peptide therapeutics market demand.

Peptide Therapeutics Market

Peptide Therapeutics Market Introduction

Peptides are a combination of two or more amino acid monomers linked by amide bonds. Researchers have demonstrated that peptides are distinguished from proteins on the basis of size. As a benchmark, molecules with less than 50 amino acids are considered peptides. In addition to the current definition of peptide, the FDA updated its definition of a biologic to include chemically synthesized polypeptides greater than 40 amino acids but less than 100 amino acids in size (synthetic proteins) and synthetic peptides 40 amino acids or less. Peptides bind to specific cell surface receptors and receptor ligands and help in the treatment of diseases by acting on the cell membrane. Therapeutic proteins and peptides are a growing class of drugs intended for clinical purposes owning to high bio-specificity. As per the peptide therapeutics industry analysis, demand for peptide therapeutics has been rising significantly due to the decline in non-peptide chemical drugs available in the market.

Request a sample to get extensive insights into the Peptide Therapeutics Market

Impact of COVID-19 on the Peptide Therapeutics Industry

The COVID-19 pandemic has had a positive impact on the global peptide therapeutics market growth. As of August 2022, 600 million infections and 6.4 million deaths were recorded across the world due to COVID-19. Peptide molecules are being used for the development of the COVID-19 vaccine. Furthermore, government authorities of various countries have supported private players in the development and usage of the COVID-19 vaccine. More than 21 peptide drugs are being used for the treatment of COVID-19, including 15 synthetic peptides in development for the treatment of acute respiratory distress syndrome (ARDS) and other respiratory illnesses caused by SARS-Cov-2 infection. Peptide drugs are being considered a treatment option for COVID-19. Thus, key players in the market have reported an increase in revenue during the COVID-19 pandemic. However, the application of peptide therapeutics in oncology, metabolic disorders, etc. has been disrupted due to a shortage of drugs and supply chain issues along with the slow progress of clinical trials related to non-COVID-19 therapeutics.

A surge in the Number of Cancer and Other Chronic Disease Patients drives Cancer Segment

In terms of application, the cancer segment dominated the global market in 2021. Cancer is the leading cause of death globally. According to the World Health Organization, cancer accounted for nearly 10 million deaths globally in 2020. Chemotherapy, the major mode of treatment for cancer, is facing major challenges due to its inability to deliver the correct amount of drug directly, which negatively affects the normal cells in the body. The application of therapeutic peptides in cancer treatment has opened a promising avenue for future growth of the global peptide therapeutics business, as it has the ability to deliver drugs with specific binding sites. Peptide-based therapeutic vaccines have attracted attention as one of the most effective treatments for tumor immunotherapy over the last few years. A rise in the prevalence and incidence rate of other chronic conditions such as Alzheimer's, diabetes, cardiac diseases, and immune disorders, owing to the increase in the geriatric population, is projected to propel the global peptide and Alzheimer's peptide therapeutics markets in the next few years.

Request a custom report on Peptide Therapeutics Market

Faster & Better Bioavailability and Quicker Onset Time Fueling Parenteral Segment

Based on the route of administration, the global peptide therapeutics industry has been classified into parenteral, oral, and others. The parenteral segment dominated the global market in 2021. Parenteral is the most common route of administration, as it ensures faster and better bioavailability, faster onset time, and better treatment outcomes. However, advancement in drug delivery technologies has led to a change in the trend of the route of administration of therapeutic peptides.

Minimal Waste and High Peptide Purity & Yield Bolstering Liquid Phase Segment

Based on technology, the liquid phase segment held the largest share of the global peptide therapeutics market in 2021. Liquid phase synthesis is usually favored for peptides, which have less than 15 amino acids in length. Liquid-phase peptide synthesis provides economies of scale for the manufacturing of peptides. Minimal waste and high peptide purity and yield are the key advantages of this technology.

Usage in Drugs for Treatment of Cancer and Tumors Augmenting Immunopeptides Segment

In terms of the type of molecule, the immunopeptide segment is likely to grow at a rapid pace during the forecast period owing to the rise in the usage of immunopeptides in drugs for the treatment of cancer and tumors. The high prevalence of cancer and the surge in the incidence rate of new cancer cases are likely to drive the immunopeptides segment during the forecast period.

Stringent Quality Systems and Standards Requirements Driving In-house Segment

Based on the API peptide type, the in-house segment dominated the global market in 2021. However, API manufacturers prefer to outsource peptide manufacturing to contract manufacturing organizations (CMOs) operating in the biosimilar market due to difficulties in manufacturing owing to the high-quality standards implemented by regulatory authorities. For instance, Bachem and Peptisyntha provide end-to-end API peptide manufacturing and possess the expertise and high-end technology for various types of peptides. Nevertheless, the shift is likely to be gradual, as most API peptide companies still prefer to manufacture in-house due to stringent quality systems and standards requirements.

Regional Outlook of the Global Peptide Therapeutics Industry

North America is projected to dominate the global market for peptide therapeutics during the forecast period. Well-established healthcare infrastructure, high-priced peptide therapeutics drugs, and favorable reimbursement policies are augmenting the peptide therapeutics market growth in the region.

The market in Asia Pacific is anticipated to grow at a high CAGR during the forecast period due to the rise in the prevalence of infectious diseases in the region. The increase in the geriatric population and surge in healthcare expenditure are fueling the market in the Asia Pacific. Furthermore, a large patient pool and high demand for newer advanced therapies are key factors likely to boost the market for peptide therapeutics in Asia Pacific.

Analysis of Key Players in the Global Peptide Therapeutics Business

The peptide therapeutics market report includes vital information about leading players in the global market. Companies are adopting product launches, divestitures, mergers & acquisitions, and partnership strategies to enhance their peptide therapeutics industry share. Amgen, Inc., Bachem Holding AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Pfizer, Inc., Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd. are the prominent players operating in the global market.

Key Developments in the Global Peptide Therapeutics market

  • In December 2022, ONL Therapeutics, Inc., a Michigan-based biopharmaceutical company that develops novel therapies, secured a US$ 46.9 Mn in a Series B financing round held in December 2020. This fund would be utilized to develop peptide manufacturing to prepare for IND application for phase 2 study.
  • In June 2022, EQT Life Sciences announced the second round of funding of US$ 25 Mn for Ariceum Therapeutics, a private biotech company developing a radiopharmaceutical product. The funding would enable Ariceum to develop satoreotide, its lead asset, and proprietary peptide derivative.

Each of these players has been profiled in the peptide therapeutics market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Peptide Therapeutics Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 39.34 Bn

Market Forecast Value in 2031

More than US$ 91.25 Bn

Growth Rate (CAGR) for 2022–2031

8.8%

Forecast Period

2022–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional-level analysis. Moreover, the qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis/ranking by company (2021)
  • Company profiles section includes overview, product portfolio, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Application
    • Cancer
    • Metabolic
    • CVD
    • Respiratory
    • GIT
    • Anti-infective
    • Dermatology
    • CNS
    • Renal
  • Route of Administration
    • Parenteral
    • Oral
  • Type
    • Innovative
    • Generic
  • Technology
    • Liquid Phase
    • Solid Phase
    • Hybrid Phase
  • Type of Molecule
    • Vasopressin
    • Somatostatin
    • Calcitonin
    • Natriuretic
  • API Peptide Type
    • In-house
    • CMO

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Amgen, Inc.
  • Bachem Holding AG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

What is the anticipated CAGR of the peptide therapeutics market in the forecast period?

The global market for peptide therapeutics is to expand at a CAGR of 8.8% from 2022 to 2031

What are the key driving factors for the growth of the peptide therapeutics industry?

The Peptide therapeutics market is driven by a rise in the adoption of hybrid technologies to achieve their economies of scale

Which region is expected to project the highest market share for peptide therapeutics in the global market?

North America accounted for a major share of the global market

Which is the rising prominent segment in the peptide therapeutics business?

The cancer segment held the highest share on account of its increasing prevalence all across the world

Who are the key players in the global peptide therapeutics industry?

Key players in the global market for peptide therapeutics include Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Sanofi, Pfizer Inc., Novartis AG, GlaxoSmithKline plc., F.Hoffmann-La Roche Ltd.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Peptide Therapeutics Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Peptide Therapeutics Market Analysis and Forecast, 2017–2031

    5. Key Insights

        5.1. White Space Analysis

        5.2. Porter’s Analysis

        5.3. Pipeline Analysis (Phase III)

        5.4. Peptide Drug Chemical Structure Trend Analysis

        5.5. Separation Media for Peptide Drug Manufacturing

        5.6. Covid-19 Impact Analysis

    6. Global Peptide Therapeutics Market Analysis and Forecast, by Application

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Application, 2017–2031

            6.3.1. Cancer

            6.3.2. Metabolic

            6.3.3. CVD

            6.3.4. Respiratory

            6.3.5. GIT

            6.3.6. Anti-infective

            6.3.7. Dermatology

            6.3.8. CNS

            6.3.9. Renal

        6.4. Market Attractiveness Analysis, by Application

    7. Global Peptide Therapeutics Market Analysis and Forecast, by Route of Administration

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Route of Administration, 2017–2031

            7.3.1. Parenteral

            7.3.2. Oral

        7.4. Market Attractiveness Analysis, by Route of Administration

    8. Global Peptide Therapeutics Market Analysis and Forecast, by Type

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by Type, 2017–2031

            8.3.1. Innovative

            8.3.2. Generic

        8.4. Market Attractiveness Analysis, by Type

    9. Global Peptide Therapeutics Market Analysis and Forecast, by Technology

        9.1. Introduction & Definition

        9.2. Key Findings / Developments

        9.3. Market Value Forecast, by Technology, 2017–2031

            9.3.1. Liquid Phase

            9.3.2. Solid Phase

            9.3.3. Hybrid Phase

        9.4. Market Attractiveness Analysis, by Technology

    10. Global Peptide Therapeutics Market Analysis and Forecast, by Type of Molecule

        10.1. Introduction & Definition

        10.2. Key Findings / Developments

        10.3. Market Value Forecast, by Type of Molecule, 2017–2031

            10.3.1. Vasopressin

            10.3.2. Somatostatin

            10.3.3. Calcitonin

            10.3.4. Natriuretic

        10.4. Market Attractiveness Analysis, by Type of Molecule

    11. Global Peptide Therapeutics Market Analysis and Forecast, by API Peptide Type

        11.1. Introduction & Definition

        11.2. Key Findings / Developments

        11.3. Market Value Forecast, by API Peptide Type ,2017–2031

            11.3.1. In-house

            11.3.2. CMO

        11.4. Market Attractiveness Analysis, by API Peptide Type

    12. Global Peptide Therapeutics Market Analysis and Forecast, by Region

        12.1. Key Findings

        12.2. Market Value Forecast, by Region

            12.2.1. North America

            12.2.2. Europe

            12.2.3. Asia Pacific

            12.2.4. Latin America

            12.2.5. Middle East & Africa

        12.3. Market Attractiveness Analysis, by Region

    13. North America Peptide Therapeutics Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Application,2017–2031

            13.2.1. Cancer

            13.2.2. Metabolic

            13.2.3. CVD

            13.2.4. Respiratory

            13.2.5. GIT

            13.2.6. Anti-infective

            13.2.7. Dermatology

            13.2.8. CNS

            13.2.9. Renal

        13.3. Market Value Forecast, by End-user,2017–2031

            13.3.1. Parenteral

            13.3.2. Oral

        13.4. Market Value Forecast, by Type, 2017–2031

            13.4.1. Innovative

            13.4.2. Generic

        13.5. Market Value Forecast, by Technology, 2017–2031

            13.5.1. Liquid Phase

            13.5.2. Solid Phase

            13.5.3. Hybrid Phase

        13.6. Market Value Forecast, by Type of Molecule, 2017–2031

            13.6.1. Vasopressin

            13.6.2. Somatostatin

            13.6.3. Calcitonin

            13.6.4. Natriuretic

        13.7. Market Value Forecast, by API Peptide Type, 2017–2031

            13.7.1. In-house

            13.7.2. CMO

        13.8. Market Value Forecast, by Country, 2017–2031

            13.8.1. U.S.

            13.8.2. Canada

        13.9. Market Attractiveness Analysis

            13.9.1. By Application

            13.9.2. By Route of Administration

            13.9.3. By Type

            13.9.4. By Technology

            13.9.5. By Type of Molecule

            13.9.6. By API Peptide Type

            13.9.7. By Country

    14. Europe Peptide Therapeutics Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Application, 2017–2031

            14.2.1. Cancer

            14.2.2. Metabolic

            14.2.3. CVD

            14.2.4. Respiratory

            14.2.5. GIT

            14.2.6. Anti-infective

            14.2.7. Dermatology

            14.2.8. CNS

            14.2.9. Renal

        14.3. Market Value Forecast, by End-user, 2017–2031

            14.3.1. Parenteral

            14.3.2. Oral

        14.4. Market Value Forecast, by Type, 2017–2031

            14.4.1. Innovative

            14.4.2. Generic

        14.5. Market Value Forecast, by Technology, 2017–2031

            14.5.1. Liquid Phase

            14.5.2. Solid Phase

            14.5.3. Hybrid Phase

        14.6. Market Value Forecast, by Type of Molecule, 2017–2031

            14.6.1. Vasopressin

            14.6.2. Somatostatin

            14.6.3. Calcitonin

            14.6.4. Natriuretic

        14.7. Market Value Forecast, by API Peptide Type, 2017–2031

            14.7.1. In-house

            14.7.2. CMO

        14.8. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.8.1. Germany

            14.8.2. U.K.

            14.8.3. France

            14.8.4. Spain

            14.8.5. Italy

            14.8.6. Rest of Europe

        14.9. Market Attractiveness Analysis

            14.9.1. By Application

            14.9.2. By Route of Administration

            14.9.3. By Type

            14.9.4. By Technology

            14.9.5. By Type of Molecule

            14.9.6. By API Peptide Type

            14.9.7. By Country/Sub-region

    15. Asia Pacific Peptide Therapeutics Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast, by Application, 2017–2031

            15.2.1. Cancer

            15.2.2. Metabolic

            15.2.3. CVD

            15.2.4. Respiratory

            15.2.5. GIT

            15.2.6. Anti-infective

            15.2.7. Dermatology

            15.2.8. CNS

            15.2.9. Renal

        15.3. Market Value Forecast, by End-user, 2017–2031

            15.3.1. Parenteral

            15.3.2. Oral

        15.4. Market Value Forecast, by Type, 2017–2031

            15.4.1. Innovative

            15.4.2. Generic

        15.5. Market Value Forecast, by Technology, 2017–2031

            15.5.1. Liquid Phase

            15.5.2. Solid Phase

            15.5.3. Hybrid Phase

        15.6. Market Value Forecast, by Type of Molecule, 2017–2031

            15.6.1. Vasopressin

            15.6.2. Somatostatin

            15.6.3. Calcitonin

            15.6.4. Natriuretic

        15.7. Market Value Forecast, by API Peptide Type, 2017–2031

            15.7.1. In-house

            15.7.2. CMO

        15.8. Market Value Forecast, by Country/Sub-region, 2017–2031

            15.8.1. China

            15.8.2. Japan

            15.8.3. India

            15.8.4. Australia & New Zealand

            15.8.5. Rest of Asia Pacific

        15.9. Market Attractiveness Analysis

            15.9.1. By Application

            15.9.2. By Route of Administration

            15.9.3. By Type

            15.9.4. By Technology

            15.9.5. By Type of Molecule

            15.9.6. By API Peptide Type

            15.9.7. By Country/Sub-region

    16. Latin America Peptide Therapeutics Market Analysis and Forecast

        16.1. Introduction

            16.1.1. Key Findings

        16.2. Market Value Forecast, by Application, 2017–2031

            16.2.1. Cancer

            16.2.2. Metabolic

            16.2.3. CVD

            16.2.4. Respiratory

            16.2.5. GIT

            16.2.6. Anti-infective

            16.2.7. Dermatology

            16.2.8. CNS

            16.2.9. Renal

        16.3. Market Value Forecast, by End-user, 2017–2031

            16.3.1. Parenteral

            16.3.2. Oral

        16.4. Market Value Forecast, by Type, 2017–2031

            16.4.1. Innovative

            16.4.2. Generic

        16.5. Market Value Forecast, by Technology,2017–2031

            16.5.1. Liquid Phase

            16.5.2. Solid Phase

            16.5.3. Hybrid Phase

        16.6. Market Value Forecast, by Type of Molecule, 2017–2031

            16.6.1. Vasopressin

            16.6.2. Somatostatin

            16.6.3. Calcitonin

            16.6.4. Natriuretic

        16.7. Market Value Forecast, by API Peptide Type, 2017–2031

            16.7.1. In-house

            16.7.2. CMO

        16.8. Market Value Forecast, by Country/Sub-region, 2017–2031

            16.8.1. Brazil

            16.8.2. Mexico

            16.8.3. Rest of Latin America

        16.9. Market Attractiveness Analysis

            16.9.1. By Application

            16.9.2. By Route of Administration

            16.9.3. By Type

            16.9.4. By Technology

            16.9.5. By Type of Molecule

            16.9.6. By API Peptide Type

            16.9.7. By Country/Sub-region

    17. Middle East & Africa Peptide Therapeutics Market Analysis and Forecast

        17.1. Introduction

            17.1.1. Key Findings

        17.2. Market Value Forecast, by Application, 2017–2031

            17.2.1. Cancer

            17.2.2. Metabolic

            17.2.3. CVD

            17.2.4. Respiratory

            17.2.5. GIT

            17.2.6. Anti-infective

            17.2.7. Dermatology

            17.2.8. CNS

            17.2.9. Renal

        17.3. Market Value Forecast, by End-user, 2017–2031

            17.3.1. Parenteral

            17.3.2. Oral

        17.4. Market Value Forecast, by Type, 2017–2031

            17.4.1. Innovative

            17.4.2. Generic

        17.5. Market Value Forecast, by Technology, 2017–2031

            17.5.1. Liquid Phase

            17.5.2. Solid Phase

            17.5.3. Hybrid Phase

        17.6. Market Value Forecast, by Type of Molecule, 2017–2031

            17.6.1. Vasopressin

            17.6.2. Somatostatin

            17.6.3. Calcitonin

            17.6.4. Natriuretic

        17.7. Market Value Forecast, by API Peptide Type, 2017–2031

            17.7.1. In-house

            17.7.2. CMO

        17.8. Market Value Forecast, by Country/Sub-region, 2017–2031

            17.8.1. GCC Countries

            17.8.2. South Africa

            17.8.3. Rest of Middle East & Africa

        17.9. Market Attractiveness Analysis

            17.9.1. By Application

            17.9.2. By Route of Administration

            17.9.3. By Type

            17.9.4. By Technology

            17.9.5. By Type of Molecule

            17.9.6. By API Peptide Type

            17.9.7. By Country/Sub-region

    18. Competition Landscape

        18.1. Market Player – Competition Matrix (by tier and size of companies)

        18.2. Market Share Analysis, by Company, 2021

        18.3. Company Profiles

            18.3.1. Amgen, Inc.

                18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.1.2. Product Portfolio

                18.3.1.3. SWOT Analysis

                18.3.1.4. Strategic Overview

            18.3.2. Bachem Holding AG

                18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.2.2. Product Portfolio

                18.3.2.3. SWOT Analysis

                18.3.2.4. Strategic Overview

            18.3.3. Eli Lilly and Company

                18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.3.2. Product Portfolio

                18.3.3.3. SWOT Analysis

                18.3.3.4. Strategic Overview

            18.3.4. F. Hoffmann-La Roche Ltd.

                18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.4.2. Product Portfolio

                18.3.4.3. SWOT Analysis

                18.3.4.4. Strategic Overview

            18.3.5. GlaxoSmithKline plc

                18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.5.2. Product Portfolio

                18.3.5.3. SWOT Analysis

                18.3.5.4. Strategic Overview

            18.3.6. Novartis AG

                18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.6.2. Product Portfolio

                18.3.6.3. SWOT Analysis

                18.3.6.4. Strategic Overview

            18.3.7. Pfizer, Inc.

                18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.7.2. Product Portfolio

                18.3.7.3. SWOT Analysis

                18.3.7.4. Strategic Overview

            18.3.8. Sanofi

                18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.8.2. Product Portfolio

                18.3.8.3. SWOT Analysis

                18.3.8.4. Strategic Overview

            18.3.9. Takeda Pharmaceutical Company Limited

                18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.9.2. Product Portfolio

                18.3.9.3. SWOT Analysis

                18.3.9.4. Strategic Overview

            18.3.10. Teva Pharmaceutical Industries Ltd.

                18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                18.3.10.2. Product Portfolio

                18.3.10.3. SWOT Analysis

                18.3.10.4. Strategic Overview

    List of Table

    Table 01: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021–2031

    Table 02: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2021–2031

    Table 03: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

    Table 04: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021–2031

    Table 05: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021–2031

    Table 06: Global API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

    Table 07: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Region, 2021–2031

    Table 08: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country, 2021–2031

    Table 09: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021–2031

    Table 10: North America Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2021–2031

    Table 11: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

    Table 12: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021–2031

    Table 13: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021–2031

    Table 14: North America API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

    Table 15: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2021–2031

    Table 16: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021–2031

    Table 17: Europe Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2021–2031

    Table 18: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

    Table 19: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021–2031

    Table 20: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021–2031

    Table 21: Europe API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

    Table 22: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2021–2031

    Table 23: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021–2031

    Table 24: Asia Pacific Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2021–2031

    Table 25: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

    Table 26: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021–2031

    Table 27: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021–2031

    Table 28: Asia Pacific API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

    Table 29: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2021–2031

    Table 30: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021–2031

    Table 31: Latin America Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2021–2031

    Table 32: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

    Table 33: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021–2031

    Table 34: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021–2031

    Table 35: Latin America API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

    Table 36: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2021–2031

    Table 37: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021–2031

    Table 38: Middle East & Africa Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2021–2031

    Table 39: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

    Table 40: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021–2031

    Table 41: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021–2031

    Table 42: Middle East & Africa API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

    List of Figures

    Figure 01: Global Peptide Therapeutics Market Value Share Analysis, by Application, 2021 and 2031

    Figure 02: Global Cancer Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

    Figure 03: Global Metabolic Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

    Figure 04: Global CVD Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

    Figure 05: Global Respiratory Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

    Figure 06: Global GIT Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

    Figure 07: Global Anti-infective Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

    Figure 08: Global Dermatology Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

    Figure 09: Global CNS Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

    Figure 10: Global Renal Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

    Figure 11: Global Others Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

    Figure 12: Global Peptide Therapeutics Market Attractiveness Analysis, by Application, 2022–2031

    Figure 13: Global Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031

    Figure 14: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Parenteral, 2021–2031

    Figure 15: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Oral, 2021–2031

    Figure 16: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Others, 2021–2031

    Figure 17: Global Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

    Figure 18: Global Peptide Therapeutics Market Value Share Analysis, by Type, 2021 and 2031

    Figure 19: Global Innovative Peptide Therapeutics Market Size (US$ Mn), 2021–2031

    Figure 20: Global Generic Peptide Therapeutics Market Size (US$ Mn), 2021–2031

    Figure 21: Global Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031

    Figure 21: Global Peptide Therapeutics Market Value Share Analysis, by Technology, 2021 and 2031

    Figure 22: Global Liquid Phase Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

    Figure 23: Global Solid Phase Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

    Figure 24: Global Hybrid Phase Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

    Figure 25: Global Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022–2031

    Figure 26: Global Peptide Therapeutics Market Value Share Analysis, by Type of Molecules, 2021 and 2031

    Figure 27: Global Vasopressin Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

    Figure 28: Global Somatostatins Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

    Figure 29: Global Calcitonin Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

    Figure 30: Global Immunopeptides Therapeutics Market Size Forecast (US$ Mn), 2021–2031

    Figure 31: Global Natriuretic Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

    Figure 32: Global Other Peptides Therapeutics Market Size Forecast (US$ Mn), 2021–2031

    Figure 33: Global Peptide Therapeutics Market Attractiveness Analysis, by Type of Molecule, 2022–2031

    Figure 34: Global API Peptide Therapeutics Market Value Share Analysis, by Type, 2021 and 2031

    Figure 35: Global In-house Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

    Figure 36: Global CMO Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

    Figure 37: Global API Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031

    Figure 38: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

    Figure 39: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

    Figure 40: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

    Figure 41: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

    Figure 42: MEA Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

    Figure 43: Global Peptide Therapeutics Market Attractiveness Analysis, by Region, 2022–2031

    Figure 44: U.S. Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

    Figure 45: Canada Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

    Figure 46: North America Peptide Therapeutics Market Attractiveness Analysis, by Country, 2022–2031

    Figure 47: North America Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

    Figure 48: North America Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031

    Figure 49: North America Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022–2031

    Figure 50: Germany Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

    Figure 51: U.K. Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

    Figure 52: France Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

    Figure 53: Italy Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

    Figure 54: Spain Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

    Figure 55: Rest of Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

    Figure 56: Europe Peptide Therapeutics Market Attractiveness Analysis, by Country, 2022–2031

    Figure 57: Europe Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

    Figure 58: Europe Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031

    Figure 59: Europe Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022–2031

    Figure 60: Japan Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

    Figure 61: China Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

    Figure 62: India Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

    Figure 63: Rest of APAC Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

    Figure 64: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 65: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

    Figure 66: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031

    Figure 67: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022–2031

    Figure 68: Brazil Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

    Figure 69: Mexico Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

    Figure 70: Rest of LATAM Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

    Figure 71: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 72: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

    Figure 73: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031

    Figure 74: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022–2031

    Figure 75: South Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

    Figure 76: Saudi Arabia Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

    Figure 77: Rest of MEA Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

    Figure 78: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 79: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

    Figure 80: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031

    Figure 81: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022–2031

    Figure 82: Peptide Therapeutics Market Share Analysis, by Company, 2021

Copyright © Transparency Market Research, Inc. All Rights reserved

We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic.

By clicking "Accept All", you consent to our use of cookies. Privacy Policy